KLY.V · Kalytera Therapeutics, Inc

-

Please sign in to comment on KLY.V

1 Comment

Admin

4 years ago

Kalytera Therapeutics, Inc is currently in a long term downtrend where the price is trading 2.7% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Kalytera Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has increased by 57.7% to $-413K since the same quarter in the previous year.

Finally, its free cash flow grew by 124.0% to $267K since the same quarter in the previous year.

Based on the above factors, Kalytera Therapeutics, Inc gets an overall score of 3/5.

Sector	Healthcare
Industry	Biotechnology
Exchange	V
CurrencyCode	CAD
ISIN	CA48349P1036

Beta	2.92
PE Ratio	None
Target Price	0.12
Dividend Yield	0.0%
Market Cap	26M

ABOUT

Kalytera Therapeutics, Inc

Kalytera Therapeutics, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing therapies for patients with unmet medical needs. Kalytera Therapeutics, Inc. was founded in 2014 and is headquartered in San Rafael, California.

KLY.V · Kalytera Therapeutics, Inc

-

Kalytera Therapeutics, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Kalytera Therapeutics, Inc using a moving average strategy